Hyun-Woong Cho, MD, PhD

home / authors / hyun-woong-cho-md-phd

Hyun-Woong Cho, MD, PhD, is part of the Department of Obstetrics and Gynecology at Korea University College of Medicine

Articles

Hyun Woong Cho, MD, PhD

Dr Cho on the Investigation of Niraparib/Bevacizumab in Platinum-Sensitive, Recurrent Ovarian Cancer

Hyun-Woong Cho, MD, PhD
April 22nd 2025

Hyun Woong Cho, MD, PhD, explains the rationale for assessing niraparib/bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Read More

Hyun-Woong Cho, MD, PhD, Department of Obstetrics and Gynecology, Korea University College of Medicine

Dr Cho on Niraparib Rechallenge Plus Bevacizumab in Platinum-Sensitive, Recurrent Ovarian Cancer

Hyun-Woong Cho, MD, PhD
March 21st 2025

Hyun-Woong Cho, MD, PhD, discusses the efficacy of maintenance therapy with niraparib plus bevacizumab in platinum-sensitive, recurrent ovarian cancer.

Read More

Latest Updated Articles

Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Vivek G Patel, MD
Published: April 2nd 2025 | Updated: May 2nd 2025
Dr Patel on Choosing Between Mosunetuzumab and Epcoritamab in Follicular Lymphoma
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer